{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:07:48Z","timestamp":1784365668594,"version":"3.55.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.breast.2021.12.019","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T15:08:12Z","timestamp":1640963292000},"page":"S17-S24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S1","title":["Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0035-0679","authenticated-orcid":false,"given":"Isabel T.","family":"Rubio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Sobrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.breast.2021.12.019_bib1","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/jso.26236","article-title":"Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments","volume":"123","author":"Esgueva","year":"2021","journal-title":"J\u00a0Surg Oncol"},{"issue":"11","key":"10.1016\/j.breast.2021.12.019_bib3","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","article-title":"How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study","volume":"23","author":"Mamtani","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.breast.2021.12.019_bib4","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1093\/annonc\/mdx806","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017","volume":"29","author":"Curigliano","year":"2018","journal-title":"Ann Oncol"},{"issue":"9938","key":"10.1016\/j.breast.2021.12.019_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib6","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(20)30580-5","article-title":"Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox","volume":"22","author":"Dubsky","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2021.12.019_bib7","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2019.5410","article-title":"Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: surgical results from the BrighTNess randomized clinical trial","volume":"155","author":"Golshan","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.breast.2021.12.019_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.03.023","article-title":"Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: a meta-analysis","volume":"97","author":"Criscitiello","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2021.12.019_bib9","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/bjs.10807","article-title":"Meta-analysis of neoadjuvant therapy and its impact in facilitating breast conservation in operable breast cancer","volume":"105","author":"Karakatsanis","year":"2018","journal-title":"Br J Surg"},{"issue":"6","key":"10.1016\/j.breast.2021.12.019_bib10","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","article-title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","volume":"17","author":"Gianni","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.breast.2021.12.019_bib11","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/SLA.0000000000000924","article-title":"Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial","volume":"260","author":"Boughey","year":"2014","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.breast.2021.12.019_bib12","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1245\/s10434-021-09829-8","article-title":"Oncological safety of oncoplastic level II mammoplasties after neoadjuvant chemotherapy for large breast cancers: a matched-cohort analysis","volume":"28","author":"van la Parra","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.breast.2021.12.019_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1245\/s10434-015-4921-5","article-title":"Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy","volume":"23","author":"Swisher","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib14","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PPO.0000000000000496","article-title":"Local treatment of triple-negative breast cancer","volume":"27","author":"Machiels","year":"2021","journal-title":"Cancer J"},{"issue":"7","key":"10.1016\/j.breast.2021.12.019_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.breast.2021.12.019_bib16","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.breast.2021.12.019_bib17","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.breast.2013.11.007","article-title":"High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer","volume":"23","author":"Criscitiello","year":"2014","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.breast.2021.12.019_bib19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrclinonc.2015.46","article-title":"Ki67--no evidence for its use in node-positive breast cancer","volume":"12","author":"Andre","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"10.1016\/j.breast.2021.12.019_bib20","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.2010.31.6950","volume":"29","author":"Ellis","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.breast.2021.12.019_bib21","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1245\/s10434-020-08888-7","article-title":"How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery?","volume":"27","author":"Montagna","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.breast.2021.12.019_bib22","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ejca.2014.05.010","article-title":"Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase II trial","volume":"50","author":"Fontein","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.breast.2021.12.019_bib23","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-021-09715-3","article-title":"Changes in management strategy and impact of neoadjuvant therapy on extent of surgery in invasive lobular carcinoma of the breast: analysis of the national cancer database (NCDB)","author":"Mukhtar","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.breast.2021.12.019_bib24","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1245\/s10434-020-08530-6","article-title":"The landmark series: neoadjuvant endocrine therapy for breast cancer","volume":"27","author":"Weiss","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"10.1016\/j.breast.2021.12.019_bib25","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.breast.2021.12.019_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1245\/s10434-016-5600-x","article-title":"Chemosensitivity and endocrine sensitivity in clinical luminal breast cancer patients in the prospective neoadjuvant breast Registry Symphony trial (NBRST) predicted by molecular subtyping","volume":"24","author":"Whitworth","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib27","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-018-4964-y","article-title":"Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study","volume":"173","author":"Iwata","year":"2019","journal-title":"Breast Cancer Res Treat"},{"issue":"14","key":"10.1016\/j.breast.2021.12.019_bib28","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.breast.2021.12.019_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"33","author":"Boileau","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.breast.2021.12.019_bib30","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2021.12.019_bib31","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1245\/s10434-017-6270-z","article-title":"Intraoperative ultrasound-guided excision of axillary clip in patients with node-positive breast cancer treated with neoadjuvant therapy (ilina trial) : a new tool to guide the excision of the clipped node after neoadjuvant treatment","volume":"25","author":"Siso","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.breast.2021.12.019_bib32","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2021.12.019_bib33","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/SLA.0000000000000558","article-title":"Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure","volume":"261","author":"Donker","year":"2015","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.breast.2021.12.019_bib34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/SLA.0000000000001375","article-title":"Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance)","volume":"263","author":"Boughey","year":"2016","journal-title":"Ann Surg"},{"key":"10.1016\/j.breast.2021.12.019_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.breast.2020.04.006","article-title":"Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic","volume":"52","author":"Curigliano","year":"2020","journal-title":"Breast"},{"key":"10.1016\/j.breast.2021.12.019_bib36","first-page":"1","article-title":"Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic","author":"Park","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2021.12.019_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0720-048X(03)00081-0","article-title":"Preoperative estimation of the pathological breast tumour size by physical examination, mammography and ultrasound: a prospective study on 105 invasive tumours","volume":"48","author":"Bosch","year":"2003","journal-title":"Eur J Radiol"},{"issue":"2","key":"10.1016\/j.breast.2021.12.019_bib38","doi-asserted-by":"crossref","first-page":"290","DOI":"10.2214\/AJR.16.17223","article-title":"Multimodality imaging for evaluating response to neoadjuvant chemotherapy in breast cancer","volume":"208","author":"Rauch","year":"2017","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.breast.2021.12.019_bib39","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1148\/radiol.2017170180","article-title":"Imaging neoadjuvant therapy response in breast cancer","volume":"285","author":"Fowler","year":"2017","journal-title":"Radiology"},{"key":"10.1016\/j.breast.2021.12.019_bib40","doi-asserted-by":"crossref","first-page":"109098","DOI":"10.1016\/j.ejrad.2020.109098","article-title":"Efficacy of shear-wave elastography versus dynamic optical breast imaging for predicting the pathological response to neoadjuvant chemotherapy in breast cancer","volume":"129","author":"Zhang","year":"2020","journal-title":"Eur J Radiol"},{"issue":"6","key":"10.1016\/j.breast.2021.12.019_bib41","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1038\/bjc.2013.473","article-title":"Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy","volume":"109","author":"Marinovich","year":"2013","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.breast.2021.12.019_bib42","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/jnci\/djs528","article-title":"Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy","volume":"105","author":"Marinovich","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.breast.2021.12.019_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","article-title":"The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review","volume":"4","author":"Lobbes","year":"2013","journal-title":"Insights Imaging"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10549-012-2033-5","article-title":"Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer?","volume":"135","author":"Wu","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41523-020-00203-7","article-title":"Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL","volume":"6","author":"Li","year":"2020","journal-title":"NPJ Breast Cancer"},{"issue":"2","key":"10.1016\/j.breast.2021.12.019_bib46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/RLI.0000000000000518","article-title":"Impact of machine learning with multiparametric magnetic resonance imaging of the breast for early prediction of response to neoadjuvant chemotherapy and survival outcomes in breast cancer patients","volume":"54","author":"Tahmassebi","year":"2019","journal-title":"Invest Radiol"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib47","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13058-017-0899-1","article-title":"Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging","volume":"19","author":"Iotti","year":"2017","journal-title":"Breast Cancer Res"},{"issue":"1","key":"10.1016\/j.breast.2021.12.019_bib48","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.sult.2017.08.005","article-title":"Contrast enhanced spectral mammography: a review","volume":"39","author":"Patel","year":"2018","journal-title":"Semin Ultrasound CT MR"},{"issue":"1112","key":"10.1016\/j.breast.2021.12.019_bib49","doi-asserted-by":"crossref","first-page":"20200301","DOI":"10.1259\/bjr.20200301","article-title":"The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis","volume":"93","author":"Tang","year":"2020","journal-title":"Br J Radiol"},{"issue":"8","key":"10.1016\/j.breast.2021.12.019_bib50","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.7863\/ultra.15.08052","article-title":"Early evaluation of relative changes in tumor stiffness by shear wave elastography predicts the response to neoadjuvant chemotherapy in patients with breast cancer","volume":"35","author":"Jing","year":"2016","journal-title":"J\u00a0Ultrasound Med"},{"issue":"7","key":"10.1016\/j.breast.2021.12.019_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236182","article-title":"Quantitative ultrasound radiomics for therapy response monitoring in patients with locally advanced breast cancer: multi-institutional study results","volume":"15","author":"Quiaoit","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.breast.2021.12.019_bib52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1258\/ar.2012.110603","article-title":"18F-FDG PET\/CT and PET for evaluation of pathological response to neoadjuvant chemotherapy in breast cancer: a meta-analysis","volume":"53","author":"Cheng","year":"2012","journal-title":"Acta Radiol"},{"issue":"4","key":"10.1016\/j.breast.2021.12.019_bib53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clbc.2013.02.003","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography in monitoring the response of breast cancer to neoadjuvant chemotherapy: a meta-analysis","volume":"13","author":"Mghanga","year":"2013","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.breast.2021.12.019_bib54","first-page":"438647","article-title":"Molecular imaging in breast cancer: from whole-body PET\/CT to dedicated breast PET","volume":"2012","author":"Koolen","year":"2012","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2021.12.019_bib55","doi-asserted-by":"crossref","first-page":"109468","DOI":"10.1016\/j.ejrad.2020.109468","article-title":"Diagnostic accuracy of axillary staging by ultrasound in early breast cancer patients","volume":"135","author":"Riedel","year":"2021","journal-title":"Eur J Radiol"},{"issue":"3","key":"10.1016\/j.breast.2021.12.019_bib56","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2214\/AJR.17.18295","article-title":"Axillary ultrasound identifies residual nodal disease after chemotherapy: results from the American College of surgeons oncology group Z1071 trial (alliance)","volume":"210","author":"Le-Petross","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"13","key":"10.1016\/j.breast.2021.12.019_bib57","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1245\/s10434-019-07809-7","article-title":"Axillary lymph node ultrasound following neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: results from the SN FNAC study","volume":"26","author":"Morency","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.breast.2021.12.019_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.57.8401","article-title":"Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the American College of surgeons oncology group Z1071 trial (alliance)","author":"Boughey","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2021.12.019_bib59","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","article-title":"Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis","volume":"273","author":"Samiei","year":"2021","journal-title":"Ann Surg"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621010262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977621010262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:43:36Z","timestamp":1760777016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977621010262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":59,"alternative-id":["S0960977621010262"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2021.12.019","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant approach in patients with early breast cancer: patient assessment, staging, and planning","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2021.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}